Aventis Pasteur draws warning letter
FDA cites capping defects in lots of Genzyme's Thymoglobulin in warning letter to Aventis Pasteur regarding manufacturing facility in Lyon, France. In addition to other quality control failures, "numerous lots of Thymoglobulin did not meet specifications for capping defects during filling and capping operations for which you are the contract manufacturer. Nevertheless, the quality control unit did not thoroughly investigate these defects," an Aug. 16 FDA 1warning letter states. Letter follows inspection that took place in mid-March and late April 2004. Aventis Pasteur says it has responded to letter, and all issues cited are either resolved or in the process of being resolved...
You may also be interested in...
DuPont says it and P&G “have conducted extensive research on human commensals bacteria to help address metabolic health issues in humans.” The partnership "will help us further advance our probiotic innovation via a next generation solution that will prove beneficial to the health and well-being of consumers around the world,” says Paul Gama, P&G personal health care president.
Head & Shoulders airing a 30-second TV spot featuring Kansas City Chiefs quarterback Patrick Mahomes and former Pittsburgh Steelers safety Troy Polamalu competing over who gives “100%” effort in everything they do.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.